Premium
Long‐term remission of children with relapsed and secondary anaplastic large cell non‐Hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide
Author(s) -
Stockklausner Clemens,
Behnisch Wolfgang,
Mechtersheimer Gunhild,
Möller Peter,
Kulozik Andreas E.
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20838
Subject(s) - medicine , etoposide , anaplastic large cell lymphoma , dexamethasone , lymphoma , chemotherapy , regimen , large cell , oncology , refractory (planetary science) , gastroenterology , cancer , adenocarcinoma , physics , astrobiology
Anaplastic large cell lymphoma (ALCL) accounts for approximately 15% of childhood NHL. Relapsed ALCL represents a formidable challenge because outcome is poor despite the use of high‐dose chemotherapy regimens. We report two patients with relapsed T‐type and 0‐type ALCL who achieved long‐term 3rd and 4th remissions with 4‐weekly oral dexamethasone (DEX) and etoposide pulses for 2 years. This regimen also induced and maintained remission in a third patient with Nijmegen breakage syndrome (NBS) with secondary T‐type ALCL. These patients demonstrate that low‐intensity oral chemotherapy can induce long‐term remissions and offer a curative perspective in refractory, relapsed and secondary ALCL. Pediatr Blood Cancer 2008;50:126–129. © 2006 Wiley‐Liss, Inc.